132 related articles for article (PubMed ID: 22260811)
1. Complement system in psoriatic arthritis: a useful marker in response prediction and monitoring of anti-TNF treatment.
Chimenti MS; Perricone C; Graceffa D; Di Muzio G; Ballanti E; Guarino MD; Conigliaro P; Greco E; Kroegler B; Perricone R
Clin Exp Rheumatol; 2012; 30(1):23-30. PubMed ID: 22260811
[TBL] [Abstract][Full Text] [Related]
2. Complement system and rheumatoid arthritis: relationships with autoantibodies, serological, clinical features, and anti-TNF treatment.
Di Muzio G; Perricone C; Ballanti E; Kroegler B; Greco E; Novelli L; Conigliaro P; Cipriani P; Giacomelli R; Perricone R
Int J Immunopathol Pharmacol; 2011; 24(2):357-66. PubMed ID: 21658310
[TBL] [Abstract][Full Text] [Related]
3. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
Perrotta FM; Marchesoni A; Lubrano E
J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925
[TBL] [Abstract][Full Text] [Related]
4. Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers.
Iervolino S; Di Minno MN; Peluso R; Lofrano M; Russolillo A; Di Minno G; Scarpa R
J Rheumatol; 2012 Mar; 39(3):568-73. PubMed ID: 22247361
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register.
Kristensen LE; Gülfe A; Saxne T; Geborek P
Ann Rheum Dis; 2008 Mar; 67(3):364-9. PubMed ID: 17644547
[TBL] [Abstract][Full Text] [Related]
6. Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA.
Iannone F; Lopriore S; Bucci R; Scioscia C; Anelli MG; Notarnicola A; Lapadula G
Scand J Rheumatol; 2015 May; 44(3):192-9. PubMed ID: 25564882
[TBL] [Abstract][Full Text] [Related]
7. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJ; Nurmohamed MT; Dijkmans BA; Hazenberg BP; Wolbink GJ
Arthritis Rheum; 2009 Nov; 61(11):1484-90. PubMed ID: 19877087
[TBL] [Abstract][Full Text] [Related]
8. Analysis of trial data for infliximab and golimumab: baseline C-reactive protein level and prediction of therapeutic response in patients with psoriatic arthritis.
Au SC; Ramirez-Fort MK; Gottlieb AB
Arthritis Care Res (Hoboken); 2014 Jul; 66(7):1114-8. PubMed ID: 24339203
[TBL] [Abstract][Full Text] [Related]
9. Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis.
Savioli C; Ribeiro AC; Fabri GM; Calich AL; Carvalho J; Silva CA; Viana VS; Bonfá E; Siqueira JT
J Clin Rheumatol; 2012 Jun; 18(4):180-4. PubMed ID: 22647860
[TBL] [Abstract][Full Text] [Related]
10. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F
Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
[TBL] [Abstract][Full Text] [Related]
11. C-reactive protein and complement components but not other acute-phase reactants discriminate between clinical subsets and organ damage in systemic lupus erythematosus.
Amezcua-Guerra LM; Springall R; Arrieta-Alvarado AA; Rodríguez V; Rivera-Martinez E; Castillo-Martinez D; Bojalil R
Clin Lab; 2011; 57(7-8):607-13. PubMed ID: 21888025
[TBL] [Abstract][Full Text] [Related]
12. The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept.
Lubrano E; Spadaro A; Marchesoni A; Olivieri I; Scarpa R; D'Angelo S; Salvarani C; Mathieu A; Cauli A; Ferrara N; Helliwell P
Clin Exp Rheumatol; 2011; 29(1):80-4. PubMed ID: 21345296
[TBL] [Abstract][Full Text] [Related]
13. Predictors of response to TNF blockers in patients with polyarticular psoriatic arthritis.
Carvalho PD; Duarte C; Vieira-Sousa E; Cunha-Miranda L; Avila-Ribeiro P; Santos H; Bernardes M; Santos MJ; Cerqueira M; Mateus M; Nero P; Águeda A; Silva JA; Machado P
Acta Reumatol Port; 2017; 42(1):55-65. PubMed ID: 27750274
[TBL] [Abstract][Full Text] [Related]
14. Relation of Doppler ultrasound synovitis versus clinical synovitis with changes in native complement component levels in rheumatoid arthritis patients treated with biologic disease-modifying anti-rheumatic drugs.
Montoro Alvarez M; Chong OY; Janta I; González C; López-Longo J; Monteagudo I; Valor L; Garrido J; Lau IS; Rosman A; Naredo E; Carreño L
Clin Exp Rheumatol; 2015; 33(2):141-5. PubMed ID: 25665178
[TBL] [Abstract][Full Text] [Related]
15. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH
Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
[TBL] [Abstract][Full Text] [Related]
17. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug.
Söderlin MK; Petersson IF; Geborek P
Scand J Rheumatol; 2012 Feb; 41(1):1-9. PubMed ID: 22118371
[TBL] [Abstract][Full Text] [Related]
18. A clinically based protein discovery strategy to identify potential biomarkers of response to anti-TNF-α treatment of psoriatic arthritis.
Collins ES; Butt AQ; Gibson DS; Dunn MJ; Fearon U; van Kuijk AW; Gerlag DM; Pontifex E; Veale DJ; Tak PP; FitzGerald O; Pennington SR
Proteomics Clin Appl; 2016 Jun; 10(6):645-62. PubMed ID: 26108918
[TBL] [Abstract][Full Text] [Related]
19. Hepatic steatosis and disease activity in subjects with psoriatic arthritis receiving tumor necrosis factor-α blockers.
Di Minno MN; Iervolino S; Peluso R; Russolillo A; Lupoli R; Scarpa R; Di Minno G; Tarantino G;
J Rheumatol; 2012 May; 39(5):1042-6. PubMed ID: 22422493
[TBL] [Abstract][Full Text] [Related]
20. Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis.
Chandran V; Shen H; Pollock RA; Pellett FJ; Carty A; Cook RJ; Gladman DD
J Rheumatol; 2013 Jun; 40(6):866-71. PubMed ID: 23637322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]